Related Experiment Video
Updated: Aug 12, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Primary and secondary prevention of atherosclerotic disease by lipid-lowering therapies]
1Second Department of Internal Medicine, Kanazawa University School of Medicine.
Insights
Lowering serum cholesterol effectively reduces coronary heart disease (CHD) risk. Clinical trials confirm that reduced cholesterol levels lead to significant CHD prevention in various patient groups.
Area of Science:
- Cardiovascular Medicine
- Epidemiology
- Preventive Cardiology
Abstract:
Epidemiological studies have shown close relationships between serum cholesterol levels and incidences of coronary heart disease (CHD). Primary and secondary prevention trials with cholesterol lowering have shown definite corresponding reductions in CHD. 4S in secondary prevention and WOS in primary prevention of hypercholesterolemic patients, CARE and LIPID in secondary prevention and CAPS in primary prevention in patients with average serum cholesterol levels have shown reduction of CHD. LDL-apheresis is more effective than medical treatment in heterozygous FH patients with CHD. Gemfibrozil is effective in secondary prevention of low HDL-cholesterolemic patients. Thus, for primary and secondary prevention of CHD the lower serum cholesterol level is the better.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care
Hypertension IV: Drug Therapy and Lifestyle Modifications
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management

